Skip to main content

Advertisement

SpringerLink
Log in

Single-center comparison of multiple chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small-cell lung cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

To date, the best chemotherapy regimen to combine with concurrent radiotherapy in stage III non-small-cell lung cancer remains undetermined. We compared the survival outcomes and toxicities in patients who were treated with etoposide–cisplatin (EP), paclitaxel–carboplatin (PC), or vinblastine–cisplatin (VP) in one large cancer referral center.

Methods

We enrolled patients who received concurrent chemoradiotherapy at our university-affiliated hospital between January 1, 2009 and December 31, 2013. Demographic and clinical characteristics were identified. Progression-free survival (PFS) and overall survival (OS) between the different treatment groups were compared using Kaplan–Meier and Cox proportional hazards regression models. Treatment-related toxicities were also compared.

Results

A total of 107 patients were treated with EP (31.8%), PC (32.7%) or VP (35.5%). Treatment with VP was significantly superior to PC, both in terms of median PFS [29.2 vs. 10.5 months; hazard ratio (HR) 0.43; 95% CI 0.21–0.85; p = 0.01] and in terms of median OS [40.7 vs. 17.8 months; (HR) 0.42; (0.21–0.84); p = 0.01]. However, there was no survival difference between EP and either one of the other regimens, but there was significantly more toxicities reported with the use of EP (73.5%) compared to PC (44.7%) or VP (37.1%); (p = 0.001). The most frequent non-hematologic toxicities for the entire cohort were esophagitis (28%), fatigue (22.4%), pneumonitis (14%), and nephrotoxicity (9.3%).

Conclusion

Although the present study is limited by its small cohort and its retrospective nature, the results suggest that VP might be superior to PC and is less toxic than EP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Notes

  1. Dose reductions in this arm are superior to the reported toxicities because vinblastine doses on days 8;15 and 22 tend to be omitted when the patient experiences asymptomatic hematologic toxicities. Tests are usually conducted at outpatient facility and results are sent directly to the pharmacy where a decision is made in regards to the upcoming dose depending on the complete blood count.

References

  1. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30

    Article  PubMed  Google Scholar 

  2. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC et al (1990) A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323(14):940–945

    Article  CAS  PubMed  Google Scholar 

  3. Dillman RO, Herndon J, Seagren SL, Eaton WL, Green MR (1996) Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88(17):1210–1215

    Article  CAS  PubMed  Google Scholar 

  4. Rolland E, Le Chevalier T, Auperin A, Burdett S, Pignon J-P (2007) Sequential radio-chemotherapy (RT-CT) versus radiotherapy alone (RT) and concomitant RT-CT versus RT alone in locally advanced non-small cell lung cancer (NSCLC): two meta-analyses using individual patient data (IPD) from randomised clinical trials (RCTs): A1-04. J Thorac Oncol 2(8):S309–S310

    Article  Google Scholar 

  5. Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P et al (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28(13):2181–2190

    Article  PubMed  Google Scholar 

  6. Curran WJ, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S et al (2011) Sequential vs concurrent chemoradiation for stage III non-small cell lung cancer: randomized Phase III trial RTOG 9410. J Natl Cancer Inst 103(19):1452–1460

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L et al (2004) Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 46(1):87–98

    Article  PubMed  Google Scholar 

  8. Fournel P, Robinet G, Thomas P, Souquet P-J, Léna H, Vergnenégre A et al (2005) Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d’Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study. J Clin Oncol 23(25):5910–5917

    Article  CAS  PubMed  Google Scholar 

  9. Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J et al (2005) Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23(25):5883–5891

    Article  CAS  PubMed  Google Scholar 

  10. Santana-Davila R, Devisetty K, Szabo A, Sparapani R, Arce-Lara C, Gore EM et al (2015) Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data. J Clin Oncol 33(6):567–574

    Article  CAS  PubMed  Google Scholar 

  11. Wang EH, Corso CD, Rutter CE, Park HS, Chen AB, Kim AW et al (2015) Postoperative radiation therapy is associated with improved overall survival in incompletely resected stage II and III non-small-cell lung cancer. J Clin Oncol 33(25):2727–2734

    Article  CAS  PubMed  Google Scholar 

  12. Rice TW, Blackstone EH, Rusch VW (2010) Of the AJCC cancer staging manual: esophagus and esophagogastric junction. Ann Surg Oncol 17(7):1721–1724

    Article  PubMed  Google Scholar 

  13. Havemann K, Wolf M, Görg C, Hackenbruch E, Pfab R, Görg K (1992) Preclincal and clinical experience with cisplatin and carboplatin and simultaneous radiation in non-small cell lung cancer. Ann Oncol 3(suppl 3):S33–S37

    Article  Google Scholar 

  14. Schaake-Koning C, Van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houtte P et al (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326(8):524–530

    Article  CAS  PubMed  Google Scholar 

  15. Clamon G, Herndon J, Cooper R, Chang AY, Rosenman J, Green MR (1999) Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 17(1):4

    CAS  PubMed  Google Scholar 

  16. Cakir S, Egehan I (2004) A randomised clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer. Lung Cancer 43(3):309–316

    Article  PubMed  Google Scholar 

  17. Groen HJM, Van der Leest A, Fokkema E, Timmer P, Nossent G, Smit W et al (2004) Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study. Ann Oncol 15(3):427–432

    Article  CAS  PubMed  Google Scholar 

  18. Atagi S, Kawahara M, Yokoyama A, Okamoto H, Yamamoto N, Ohe Y et al (2012) Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol 13(7):671–678

    Article  CAS  PubMed  Google Scholar 

  19. Yamamoto N, Nakagawa K, Nishimura Y, Tsujino K, Satouchi M, Kudo S et al (2010) Phase III study comparing second-and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 28(23):3739–3745

    Article  PubMed  Google Scholar 

  20. Gore EM, Bae K, Wong SJ, Sun A, Bonner JA, Schild SE et al (2011) Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol 29(3):272–278

    Article  PubMed  Google Scholar 

  21. Santana-Davila R, Martins R (2016) Treatment of stage IIIA non-small-cell lung cancer: a concise review for the practicing oncologist. J Oncol Pract 12(7):601–606

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology - Oncology Division, Department of Medicine, Centre Hospitalier de l’Université de Montréal (CHUM), Montreal, QC, Canada

    Samer Tabchi, Normand Blais & Mustapha Tehfe

  2. Radiation Oncology Department, Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada

    Marie-Pierre Campeau

Authors
  1. Samer Tabchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Normand Blais
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marie-Pierre Campeau
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mustapha Tehfe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mustapha Tehfe.

Ethics declarations

Conflict of interest

Samer Tabchi and Marie-Pierre Campeau declare that they have no competing interests. Normand Blais reports personal fees from Merck, Pfizer, AstraZeneca, Bristol Myers Squibb, outside the submitted work. Mustapha Tehfe reports personal fees from Lilly, Amgen, and Celegene outside the submitted work.

Ethical approval

This study was approved by the CHUM’s Institutional Review Board. No procedures were undertaken in this retrospective analysis.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tabchi, S., Blais, N., Campeau, MP. et al. Single-center comparison of multiple chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small-cell lung cancer. Cancer Chemother Pharmacol 79, 381–387 (2017). https://doi.org/10.1007/s00280-016-3226-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-016-3226-0

Keywords

Search

Navigation